Ultrasonographic Response to Polarized Light Therapy in the Treatment of Atopic Dermatitis

Terminated

• Conditions: Chronic Atopic Dermatitis
• Interventions: Device: polarized light; Drug: Topical corticosteroid ointment

• Registration Number: NCT04955951
• Lead Sponsor: Ahram Canadian University

Brief Summary

Non-atopic dermatitis (NAD) or eczema is a common inflammatory condition; potentially debilitating that can compromise quality of life. It is usually seen in childhood, but can onset within or persist into adulthood.

Detailed Description

Polarized ultraviolet-free polychromatic light is used as therapeutic option for the treatment of wound healing and dermatological conditions.

40 male patients who had atopic dermatitis in the chronic stage, they were complaining from itching, inflammation and skin thickness in the arm, wrist, hand and leg will participate in this study.

Study Timeline

• Study First Submitted: 2021-06-16
• Study Start: 2021-07-01
• Study First Submitted QC: 2021-07-07
• Study First Posted: 2021-07-09
• Primary Completion: 2021-09-15
• Status Verified: 2021-10
• Study Completion: 2022-01-15
• Last Update Submitted: 2023-08-20
• Last Update Posted: 2023-08-23

Recruitment & Eligibility

• Status: TERMINATED
• Sex: Male
• Target Recruitment: 40

Inclusion Criteria

• The patients' ages will ranged from 20 to 30 years.
• The subjects will be males.
• The duration of disease less than 1 year.

Exclusion Criteria

• patients who had skin malignancy in the area to be treated.
• The patients who had history of diabetes, circulatory or sensory disorders.
• Patients with acute infection in the area treated.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
polarized light group	polarized light	group A (20 patients) will receive Polarized light therapy
topical corticosteroid group	Topical corticosteroid ointment	group B (20 patients) will receive topical corticosteroid therapy

Primary Outcome Measures

Name	Time	Method
Ultrasonography	1-2 months	Ultrasound imaging system used to measure the thickness of the skin at the site of scale for both groups

Secondary Outcome Measures

Name	Time	Method
SCORAD Score	1-2 months	The SCORAD (Index) is the best validated scoring system in atopic dermatitis, To measure the extent of AD, the rule of nines is applied on a front/back drawing of the patient's inflammatory lesions. The extent can be graded from 0 to 100. The intensity part of the SCORAD consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness. Each item can be graded on a scale from 0 to 3. The subjective items include daily pruritus and sleeplessness. The SCORAD Index formula is: A/5 + 7B/2 + C. In this formula A is defined as the extent (0-100), B is defined as the intensity (0-18) and C is defined as the subjective symptoms (0-20). The maximal score of the SCORAD Index is 103. The objective SCORAD consist of the extent and the intensity items; the formula is A/5 + 7B/2. The maximal objective SCORAD score is 83 (with 10 additional points for severe disfiguring eczema of the face and hands).

Trial Locations

Locations (1)

Ahram Canadian University; 🇪🇬 Giza, Egypt